As New Jersey’s only NCI-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health, provides patients access to the most advanced treatment options including complex surgical procedures, sophisticated radiation therapy techniques, innovative clinical trials, immunotherapy, and precision medicine.
|
|
|
Nursing Leader to be Inducted as a Fellow of the American Academy of Nursing |
|
|
|
Carolyn Hayes, PhD, RN, NEA-BC, chief nursing officer for Oncology Services at RWJBarnabas Health and Rutgers Cancer Institute of New Jersey, has been selected as a 2021 Fellow by the American Academy of Nursing. Fellows are some of nursing's most accomplished leaders in policy, research, practice, administration, and academia. Dr. Hayes is one of 225 distinguished nursing leaders around the world to be selected for induction into the Academy, considered a significant milestone in a nurse leader’s career. Learn more
|
|
Mechanism for Development of Rare Colorectal Cancer Subtype Identified |
|
|
|
Researchers from Rutgers Cancer Institute of New Jersey recently discovered a mechanism to explain what drives the formation of mucinous colorectal adenocarcinoma, a rare subtype of colorectal cancer, and has also identified the genes responsible for the regulation of this mechanism. The study, which was published in the OnlineFirst version of Cancer Research, was led by Mijung Kwon, PhD, Rutgers Cancer Institute researcher and assistant professor of medicine at Rutgers Robert Wood Johnson Medical School along with senior author Rutgers Cancer Institute of New Jersey Director Steven K. Libutti, MD, FACS, who is also senior vice president of oncology services at RWJBarnabas Health.
|
|
Rutgers Cancer Institute Welcomes New Chief of Thoracic and Head and Neck Medical Oncology |
|
|
|
Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have named Missak Haigentz, Jr., MD, as Chief of Thoracic Medical Oncology and Head and Neck Medical Oncology and clinical director for Oncology Integration. He also has been appointed as a professor of medicine at Rutgers Robert Wood Johnson Medical School. Dr. Haigentz comes from Atlantic Health System where he established and led an NCI Community Oncology Research Program as principal investigator. In his new roles at Rutgers Cancer Institute, Dr. Haigentz will co-lead the Head and Neck Oncology Program and the Thoracic Oncology Program and collaborate with colleagues across RWJBarnabas Health in the management of patient care in these areas. Learn more
|
|
Exploring Therapeutic Strategy for T-cell Acute Lymphoblastic Leukemia |
|
|
|
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive type of leukemia with poor prognosis, highlighting the need to discover new targeted therapeutic approaches. Rutgers Cancer Institute of New Jersey resident researcher Daniel Herranz Benito, PhD, was recently awarded a 2021 AACR-Bayer Innovation and Discovery Grant (21-80-44-HERR) from the American Association for Cancer Research to further explore a novel mitochondrial uncoupling drug in the treatment of leukemia and a potential therapeutic strategy against T-ALL. Learn more about the project
|
|
|
|
|
|
|
